XOMA Corporation (XOMA) versus its Rivals Critical Contrast
XOMA Corporation (NASDAQ: XOMA) is one of 93 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare XOMA Corporation to similar businesses based off the strength of its earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and risk.
Valuation & Earnings
This table compares XOMA Corporation and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|XOMA Corporation||$12.31 million||-$30.55 million||-2.50|
|XOMA Corporation Competitors||$220.96 million||$56.99 million||-0.64|
XOMA Corporation’s peers have higher revenue and earnings than XOMA Corporation. XOMA Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently the more affordable than other companies in its industry.
Institutional & Insider Ownership
32.9% of XOMA Corporation shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 3.0% of XOMA Corporation shares are held by insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for XOMA Corporation and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|XOMA Corporation Competitors||161||542||1199||16||2.56|
XOMA Corporation currently has a consensus price target of $17.00, suggesting a potential downside of 7.05%. All “Biotechnology” companies have a potential upside of 64.56%. Given XOMA Corporation’s peers stronger consensus rating and higher possible upside, analysts clearly believe XOMA Corporation has less favorable growth aspects than its peers.
This table compares XOMA Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|XOMA Corporation Competitors||-917.28%||-186.99%||-24.41%|
Risk and Volatility
XOMA Corporation has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500. Comparatively, XOMA Corporation’s peers have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
XOMA Corporation peers beat XOMA Corporation on 8 of the 12 factors compared.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.